Antibody drug conjugate (ADC)

Bispecific antibodies
#Alentis Therapeutics #Antibody drug conjugate (ADC) #Biotechnology #Collaboration #Financing #Novo Holdings #Solid tumours

Successful collaboration to advance ADCs for solid tumours 

Novo Holdings has co-led a $181.4 million Series D financing in Alentis Therapeutics, a clinical-stage biotechnology company, headquartered in Basel, Switzerland, which is developing a pipeline of Claudin-1 (CLDN1) targeted medicines.  This financing will enable Alentis to begin Phase I/II trials for two first-in-class ADCs: ALE.P02, which targets advanced or… Read More

#Business & Investment #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Heidelberg Pharma #Infectious diseases

ADCs: The next generation of targeted therapies 

Antibody drug conjugates (ADCs) are among the hottest properties in pharma, powerful anticancer drugs that target tumours and deliver a lethal payload that destroys them, while leaving healthy tissues untouched. But there’s much more to come from this technology. DDW’s Megan Thomas explores the topic and speaks with experts in… Read More

#Exclusive Content #Opinion #Regulatory

Urinary system
#Antibody drug conjugate (ADC) #Astellas Pharma #European Commission #Oncology #Urothelial carcinoma

EU okays new first-line treatment for advanced urothelial cancer

The European Commission has granted marketing authorisation for antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) in combination with PD-1 inhibitor Keytruda (pembrolizumab) for urothelial cancer. It is approved for the first-line treatment of adult patients with unresectable or metastatic cancer, who are eligible for platinum-containing chemotherapy. The approval is based on… Read More

#News #Regulatory

Antibody drug conjugate
#Adcendo #Antibody drug conjugate (ADC) #Cancer research #Multitude Therapeutics

Agreement facilitates differentiated ADC targeting Tissue Factor 

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.  TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer,… Read More

#Cancer Research #News

Antibody drug conjugate
#Angiex #Antibody drug conjugate (ADC) #Oncology #Phase I trial #Solid tumours

Antibody-drug conjugate for solid tumours enters Phase I trials

The first patient has been dosed in a Phase I clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. Developer Angiex is focused on nuclear-delivered antibody-drug conjugates (ND-ADCs), which release therapeutic payloads directly into the nucleus or cytosol,… Read More

#Cancer Research #News

Cancer cell
#AACR #Antibody drug conjugate (ADC) #Cancer research #Drug development #Drug discovery #Zymeworks

Finding protein therapeutics for cancer treatment  

The American Association of Cancer Research (AACR) Annual Meeting took place from 5-10 April 2024 in San Diego. DDW’s Megan Thomas spoke with Dr Paul Moore, Chief Scientific Officer at Zymeworks and Dr Nina Weisser, Director of Multispecific Antibody Therapeutics at Zymeworks, about the event as well as the future… Read More

#Cancer Research #Exclusive Content

#Antibody drug conjugate (ADC) #Financing #Francis Crick Institute #Imperial College London #Myricx Bio #Start-ups

Myricx Bio announces £90m ($114m) Series A financing

UK biotech Myricx Bio has raised £90 ($114) million Series A financing to support the development of its N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) therapeutics. The round was co-led by new investors Novo Holdings and Abingworth, with additional support from British Patient Capital, Cancer Research Horizons and Eli Lilly, plus… Read More

#Business & Investment #News #Trending News

Therapeutic antibodies
#Antibody drug conjugate (ADC) #Bispecific Antibodies #Drug discovery #eBook #Therapeutic Antibodies

eBook: The impact of therapeutic antibody discovery

A new eBook, sponsored by Sino Biological, is now available for download entitled ‘The impact of therapeutic antibody discovery’. The first monoclonal antibody (mAb), Orthoclone, was approved in 1986 to help prevent rejection in organ transplantation. Since then, the US Food and Drug… Read More

#News

The impact of therapeutic antibody discovery
#Antibody drug conjugate (ADC) #Bispecific Antibodies #Drug discovery #eBook #Therapeutic Antibodies

The impact of therapeutic antibody discovery

This eBook explores the challenges and opportunities in the therapeutic antibody market, the range of applications for these therapies and the move towards more targeted and effective next-generation antibody treatments. Download this exclusive eBook to learn more about: How artificial intelligence and machine learning are benefitting antibody discovery and design… Read More

#DDW eBooks #Intelligence

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Cancer research #Funding #Pheon Therapeutics #Solid tumours

$120m raised to develop differentiated ADC pipeline 

Pheon Therapeutics has completed a $120m Series B financing to fund the development of its pipeline of next generation ADCs for a wide range of hard-to-treat cancers.  The new financing will be used to further advance Pheon’s differentiated ADC pipeline through clinical proof of concept. The first three assets are… Read More

#Business & Investment #Cancer Research #News

Antibody drug conjugate
#Accelerated assessment #Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Oncology #Solid tumours

First tumour agnostic HER2 directed ADC gets US approval

Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumours. Enhertu has been granted accelerated approval to treat patients who have received prior systemic treatment and have no satisfactory alternative… Read More

#News #Regulatory

Paris
#AI #Antibody drug conjugate (ADC) #DNA #ESMO #ESMO Targeted Anticancer Therapies Congress 2024 #RNA #Storm Therapeutics

Conversations from ESMO Targeted Anticancer Therapies Congress 2024 

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. Rausch gave an update on the latest developments from… Read More

#Exclusive Content

#Akari Therapeutics #Antibody drug conjugate (ADC) #Mergers and acquisitions #Peak Bio #Stem cells

Akari Therapeutics and Peak Bio announce merger

Biotechnology company Akari Therapeutics and biopharmaceutical company Peak Bio have announced a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Following closing, the… Read More

#Business & Investment #News

Drug discovery technology
#2024 predictions #Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Gene therapy

Key drug development trends and predictions for 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. Financial landscape In 2023, life science companies experienced a significant decrease in… Read More

#Exclusive Content #Trends & Analysis

#Antibody drug conjugate (ADC) #Bladder cancer #Breast cancer #Depression #Menopause #Oncology #Psychedelics #Women's health

New DDW Highlights podcast for 27 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  There have been some ground-breaking advances in women’s health this week, with new treatments… Read More

#News

#Antibody drug conjugate (ADC) #Bladder cancer #Breast cancer #Depression #Menopause #Oncology #Psychedelics #Women's health

This week in drug discovery (18-22 December) 

News round-up for 18-22 December by DDW Digital Content Editor Diana Spencer. There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer. In… Read More

#News